Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.37 |
| ▸ | PRKCB | P05771 | 1/20 | 0.37 |
| ▸ | PRKCA | P17252 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | MLYCD | O95822 | 1/20 | 0.36 |
| ▸ | TYMS | P04818 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6382256 | 0.90 | NPC1 (0.52) | NPC1RAB9ACTSSCTSK | |
| SCHEMBL6382259 | 0.90 | NPC1 (0.52) | NPC1RAB9ACTSSCTSK | |
| SCHEMBL6386068 | 0.88 | TRPV1 (0.44) | NPC1RAB9ACTSSCTSKTAS1R3 | |
| SCHEMBL6386072 | 0.88 | TRPV1 (0.44) | NPC1RAB9ACTSSCTSKTAS1R3 | |
| SCHEMBL6838943 | 0.88 | GAA (0.41) | NPC1RAB9ACTSSCTSKTAS1R3 | |
| SCHEMBL5255969 | 0.88 | GAA (0.41) | NPC1RAB9ACTSSCTSKTAS1R3 | |
| SCHEMBL6381778 | 0.87 | SSTR3 (0.46) | NPC1RAB9ACTSSCTSKTAS1R3 | |
| SCHEMBL6381865 | 0.87 | ADAM17 (0.40) | CTSSCTSKTAS1R3TAS1R1TYMS | |
| SCHEMBL6380550 | 0.87 | SSTR3 (0.46) | NPC1RAB9ACTSSCTSKTAS1R3 | |
| SCHEMBL6380546 | 0.87 | SSTR3 (0.46) | NPC1RAB9ACTSSCTSKTAS1R3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248949-A1 | Benzamide nitriles | ROCHE PALO ALTO LLC | 2004-12-09 | — | — | US | claimed |
| US-7300934-B2 | Benzamide nitriles | ROCHE PALO ALTO LLC (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300934-B2 | Benzamide nitriles | ROCHE PALO ALTO LLC (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300934-B2 | Benzamide nitriles | ROCHE PALO ALTO LLC (US) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248949-A1 | Benzamide nitriles | CTSK, CTSS, CMA1 | NPC1 51/4885RAB9A 1086/4885DEGS1 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.